GC376 sodium

The stock solution (10 mM) of GC376 is prepared in DMSO and further diluted in assay buffer. The final concentrations of DMSO in the assay did not exceed 1.5% (vol/vol). The 3CLpro from NV, MD145 or MNV-1 are incubated with various concentrations (0.01 to 50 µM) of GC376 in 25 µL of assay buffer for 30 min at 37 °C. Following incubation, 25 µL of assay buffer containing substrate is added, and the mixtures are incubated in a 96-well black plate at 37 °C for 60 min. The fluorescence signals are detected using an excitation and emission wavelength of 490 and 520 nm on a fluorescence microplate reader. The RFU are calculated for each well, and the dose-dependent FRET inhibition curves are fitted with variable slope (four parameters) using GraphPad Prism software in order to determine the IC₅₀ values of GC376^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Twenty cats from 3.3-82 months of age (mean 10.4 months) with various forms of feline infectious peritonitis are accepted into a field trial. Fourteen cats presented with wet or dry-to-wet FIP and six cats presented with dry feline infectious peritonitis. GC376 is administered subcutaneously every 12 h at a dose of 15 mg/kg. Cats with neurologic signs are excluded from the study. Responses to treatment are monitored^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.